Zydus Lifesciences received FDA approval for its ANDA submission, setting the stage for commercialization and the potential to capture market share in the relevant therapeutic space. The clearance paves the way for the launch of the product, signaling an expansion of Zydus Lifesciences' domestic ANDA portfolio and a projected contribution to future revenue streams.